Definitive Contract 75A50120C00001

<p>This is a $233,343,418.86 definitive cost contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Hoffmann-La Roche Inc. on September 15, 2016. The contract is for the &quot;Combating Multi-Drug Resistance and Addressing Emerging Bacterial Threats: Discovery, Clinical Development&quot; program and has an ultimate completion date of December 31, 2026. The contract was not set aside for any specific business type.</p>

This is a definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Spero Therapeutics, Inc. for the advanced research and development of SPR994, an oral carbapenem antibiotic to treat drug-resistant Gram-negative bacterial infections. The $43,372,809.00 cost-sharing contract has a period of performance through December 31, 2025. The contract was not set aside and originated from a Broad Agency Announcement (BAA) seeking proposals to develop...

This is a $160,848,139.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Cangene Corporation for the development of anthrax therapeutics. The contract has an ultimate completion date of September 30, 2023 and utilizes a combination of pricing types. There is no set-aside designation for this award. The contract is for the research and development of medical countermeasures against anthrax, a critical component of the...

This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for multidrug-resistant Pseudomonas aeruginosa infections. This contract is not set aside for any specific...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at $12.5 billion to Pfizer Inc. for the manufacturing and delivery of 10 million treatment courses of the oral protease inhibitor PF-07321332. This award was made under the Joint PEO-CBRND &amp; BARDA Commercial Solutions Opening solicitation seeking proposals to produce a minimum of 100,000 treatment courses of advanced SARS-CoV-2 medical countermeasures by...

This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Pattern Bioscience, Inc., a biotechnology company, to develop a rapid pathogen identification and antimicrobial susceptibility testing platform. The contract, valued at $40,937,536.73, is for the verification, clinical evaluation, and U.S. Food and Drug Administration (FDA) clearance of this culture-free, phenotypic diagnostic platform. The contract is a...

This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...

This definitive cost-no-fee contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awards $15.5 million to Entasis Therapeutics Inc. to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad spectrum activity against multidrug-resistant (MDR) gram-negative ESKAPE pathogens. The work directly responds to the 2019 NIAID Omnibus Broad Agency...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Elusys Therapeutics Inc., a self-certified small disadvantaged business and manufacturer of goods, for the delivery of ANTHIM (obiltoxaximab). The contract has a firm fixed price of $124,650,623.00 and a completion date of April 30, 2027. There is no set-aside designation for this contract. Elusys Therapeutics Inc. is a subsidiary of the...

This is a $77,030,934 definitive contract awarded by the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR) to T2 Biosystems, Inc., a for-profit manufacturer, to advance the development of rapid, high-throughput, multiplexed detection of biothreat species identification and antibiotic resistance genes using T2MR technology as a countermeasure to diagnose bacterial biothreat pathogens and antibiotic resistance threats. The...